e-learning
resources
Vienna 2012
Monday, 03.09.2012
Treatment of lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib
H. Ge, S. Ni, X. Fang, N. Xu, Y. Liu, Y. Song, C. Bai (Shanghai, Nantong, China)
Source:
Annual Congress 2012 - Treatment of lung cancer
Session:
Treatment of lung cancer
Session type:
Poster Discussion
Number:
2912
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Ge, S. Ni, X. Fang, N. Xu, Y. Liu, Y. Song, C. Bai (Shanghai, Nantong, China). Synergistic therapy for NSCLC: Additive preclinical efficacy of interleukin-6 inhibitor madindoline A with crizotinib. Eur Respir J 2012; 40: Suppl. 56, 2912
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: respiratory care for newborns in resource-limited settings
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Novel anti-angiogenic pharmacotherapy strategies
Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases
Year: 2005
Emerging prognostic biomarkers in non small cell lung cancer patients: Impact of treatment with nimesulide (COX-2 inhibitor) combined with chemotherapy
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011
Combination therapy of gefitinib and CYP3A4 inhibitor on non-small-cell lung cancer patients with an
EGFR
mutation and carcinomatous meningitis
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study.
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Targeting of STAT3 and survivin with TG101209, a novel JAK2 inhibitor, enhances radiotherapy in lung cancer models
Source: Annual Congress 2010 - New insights in the pathology of lung cancer
Year: 2010
Cost-effectiveness of afatinib versus erlotinib for the treatment of squamous non-small cell lung cancer in france after a first-line platinum based therapy
Source: International Congress 2017 – Does economisation of medicine transfer into benefits for patients?
Year: 2017
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy
Source: Eur Respir J, 53 (3) 1801562; 10.1183/13993003.01562-2018
Year: 2019
Maintenance treatment with erlotinib after induction chemotherapy for advanced NSCLC
Source: Annual Congress 2011 - Recent therapeutic advances with tyrosine-kinase inhibitors in nonsmall-cell lung cancer
Year: 2011
Comparison of in-vitro anti-fibrotic effects of pirfenidone and nintedanib
Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Year: 2019
Better quality-of-life in patients with exon 19 deletion receiving first-line tyrosine kinase inhibitors for advanced non-small-cell lung cancer
Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders
Year: 2017
The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings)
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Potential therapeutic significance of CIK cells in gefitinib resistant NSCLC with EGFR mutations
Source: Annual Congress 2011 - Progress in pathology of lung cancer
Year: 2011
Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
Phase II open-label study to investigate efficacy and safety of PTK787/ZK 222584 (PTK/ZK) orally administered once daily at 1250 mg as second-line monotherapy in patients (pts) with stage IIIB/IV non-small-cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept